Drug Profile
PT 00114
Alternative Names: PT-00114; PT100114Latest Information Update: 02 May 2023
Price :
$50
*
At a glance
- Originator Protagenic Therapeutics
- Developer Charles River Laboratories; Protagenic Therapeutics
- Class Antidepressants; Anxiolytics; Peptides
- Mechanism of Action Corticotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Depressive disorders; Impulse control disorders; Neurodegenerative disorders; Opioid-related disorders
Most Recent Events
- 02 May 2023 Protagenic Therapeutics plans a phase I/IIa trial for Mental disorders in the third quarter of 2023
- 31 Dec 2022 Protagenic therapeutics has patents pending for compositions, methods and uses of a teneurin c-terminal associated peptides for treating opioid addiction(TCAP) in USA, Canada, Hong Kong and EU
- 11 Apr 2022 Protagenic therapeutics plans to re-submit an IND application with the US FDA for psychiatric illnesses and Healthy volunteers in second quarter of 2022